Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 1/2017

01-01-2017 | Book Review

Book review: Oxford textbook of oncology, 3rd edition

Editors: Kerr DJ, Haller DG, van de Velde CJ, Baumann M ISBN: 978–0–19-965,610-3 date of publication 2016 cost £230.00

Author: Andrew Davies

Published in: Supportive Care in Cancer | Issue 1/2017

Login to get access

Excerpt

It has been 15 years since the second edition of this eminent text book was published. In the interim, there have been significant advances in oncology, and so it is somewhat surprising (but welcome) to see that the third edition of the text book is much more compact than the second edition (i.e. one volume of approximately 1000 pages versus two volumes of approximately 3000 pages). Nevertheless, the third edition contains all necessary information for the non-specialist aiming to be up-to-date with the said advances in oncology. …
Metadata
Title
Book review: Oxford textbook of oncology, 3rd edition
Editors: Kerr DJ, Haller DG, van de Velde CJ, Baumann M ISBN: 978–0–19-965,610-3 date of publication 2016 cost £230.00
Author
Andrew Davies
Publication date
01-01-2017
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 1/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3469-7

Other articles of this Issue 1/2017

Supportive Care in Cancer 1/2017 Go to the issue

Erratum

Erratum to: 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy

Original Article

Impact of outpatient palliative care (PC) on symptom burden in patients with advanced cancer at a tertiary cancer center in Jordan

Original Article

Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis

Original Article

Variations in supportive care needs of patients after diagnosis of localised cutaneous melanoma: a 2-year follow-up study

Original Article

Effects of resistance exercise in women with or at risk for breast cancer-related lymphedema

Special Article

2016 Updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits